Objectives: Uterine serous carcinoma (USC) represents a rare and aggressive histologic subtype of endometrial cancer, associated with a poor prognosis. This article critically reviews the literature pertinent to the epidemiology, pathology, molecular biology, diagnosis, management, and perspectives of patients with USC. Methods: As one of a series of The Gynecologic Cancer InterGroup (GCIG) Rare Tumor Working Group in London, November 2013, we discussed about USC many times with various experts among international GCIG groups. Results: Both USC and approximately 25% of high-grade endometrioid tumors represent extensive copy number alterations, few DNA methylation changes, low estrogen and progesterone levels, and frequent P53mutations. Uterine serous carcinoma shares molecular characteristics with ovarian serous and basal-like breast carcinomas. In addition to optimal surgery, platinum-and taxane-based chemotherapy should be considered in the treatment of both early-and advanced-stage disease. The combination of radiation and chemotherapy appears to be associated with the highest survival rates. The role of radiation therapy in the management of this disease, with a high propensity for distant failures, remains elusive. Conclusions: Uterine serous carcinoma is a unique and biologically aggressive subtype of endometrial cancer and should be studied as a distinct entity. Futures studies should identify the optimized chemotherapy and radiation regimens, sequence of therapy and schedule, and the role of targeted biologic therapy.
E ndometrial cancer is the most common gynecologic malignancy in women worldwide. Most endometrial cancers present as early-stage disease, with a 5-year survival rate of greater than 85%. However, uterine serous carcinoma (USC) represents an aggressive histologic subtype of endometrial cancer; a total genome analysis has indicated that it most closely resembles high-grade endometrioid adenocarcinoma. 1 Although USC (previously named as uterine papillary serous carcinoma, and now called uterine serous carcinoma, as not only papillary lesions exist) represents less than 10% of all endometrial cancers, it accounts for more than 50% of relapses and deaths attributed to endometrial carcinoma. 2 The estimated 5-year overall survival (OS) rate for patients with USC is 18% to 27%, likely due to the clinical observation that approximately 60% to 70% of women with USC present with disease outside the uterus. Even in cases where disease is apparently confined to the corpus, the rate of recurrence is high, estimated to be 31% to 80%. 3 Improved treatment strategies are needed. Given the rarity of USC, prospective trials to determine the best treatment plans have not been feasible to date.
Epidemiology
In 1982, Hendrickson et al 2 described USC as a distinct subtype of endometrial cancer, histologically resembling serous ovarian cancer. In 1983, Bokhman 4 suggested the existence of 2 types of endometrial cancer, with distinct histologic appearance, epidemiology, and clinical course. Type I lesions are histologically endometrial endometrioid carcinoma (EEC), are usually seen in younger patients, and are associated with obesity, hyperlipidemia, and hyperestrogenism. In contrast, type II cancers include poorly differentiated endometrioid adenocarcinomas (clear cell and serous cell types), are seen in older patients, and are not associated with hormonal factors. When compared with type I tumors, type II endometrial cancers are more likely to present with metastatic disease at original diagnosis and to have a less favorable prognosis. In 2013, a new classification system for endometrial cancer using genomic analysis was published; it categorized uterine serous tumors and È25% of high-grade endometrioid tumors together as having extensive copy number alterations, few DNA methylation changes, low estrogen receptor/progesterone receptor levels, and frequent TP53 mutations. 1 Based on International Federation of Gynecology and Obstetrics (FIGO) Annual Report data, 46% of women with USC initially present with stage IIYIV disease compared with 21% of patients with EEC. 5 For all women with stage I EEC, the estimated 5-year survival rate is 80% to 90%. By contrast, only 50% to 80% of women with USC can expect this favorable prognosis. 5, 6 Unlike type I tumors, which usually recur locally and may be amenable to salvage therapy with tumor-directed radiation, USC commonly recurs at distant sites, limiting the role of radiation therapy and curative single-modality intervention after upfront radiation. 6 Data from a Surveillance, Epidemiology and End Results trial suggest a significantly lower 5-year disease-specific survival rate for 1473 patients with USC when compared with 2316 women with grade 3 EEC with either early (stages I/II, 74% vs 85%, P G 0.0001) or advanced (stages III/IV, 33% vs 54%, P G 0.0001) disease. 6 Similar 5-year survival rates were reported when comparing 148 patients with stage I USC to 325 patients with stage I, grade 3 EEC (72% vs 76%). 5 It is not uncommon for endometrial cancers with serous histology as a component to have other high-grade cell types, such as clear cell and grade 3 EEC. For protocol enrollment purposes, the US Gynecologic Oncology Group (GOG) requires that tumors classified as USC must have more than 50% of the mixed tumor histology be of serous origin. In the review by Boruta et al, 7 the presence of USC as a minor component, defined as less than 10%, was associated with a poorer prognosis when compared with tumors of pure grade 3 endometrioid histology. Boruta and colleagues' review reports associations between USC and breast cancer or between USC and hereditary breast-ovarian-cancer syndrome. 6 Further elucidation of this potential association is of value as it would impact recommendations regarding risk-reducing surgery, supporting hysterectomy at the time of prophylactic salpingooophorectomy. 8 
Pathology and Molecular Biology and Genetics
Investigators in The Cancer Genome Atlas Research Network performed an integrated genomic, transcriptomic, and proteomic characterization of 373 endometrial carcinomas, including 307 endometrioid and 66 serous or mixed histology cases, using array-and sequencing-based techniques recently reported. 1 Their findings indicate that endometrial cancers can be classified into at least 4 subtypes on the basis of molecular characteristics.
Investigation of somatic copy number alterations in endometrial carcinomas indicated that most of the serous (94%) and mixed histology (62%) cases clustered with a small proportion (12%) of endometrioid tumors in a group characterized by extremely high rates of somatic copy number alteration. This group was also characterized by frequent TP53 mutations (90%), a low rate of microsatellite instability (6%), and a lower rate of PTEN mutations than in other endometrioid tumors (11% vs 84%). Tumors in this ''serous-like'' cluster were associated with significantly worse progression-free survival (PFS) than tumors in the other 3 somatic copy number alteration clusters, which contained almost exclusively endometrioid tumors (97%).
With a combination of somatic nucleotide substitutions, microsatellite instability status, and somatic copy number alteration, the endometrial tumors could be classified into 4 groups: (1) an ultramutated group with unusually high mutation frequencies despite microsatellite stability and a unique nucleotide change spectrum (POLE group); (2) a hypermutated group with microsatellite instability, most with MLH1 promoter methylation (microsatellite instability group); (3) a lower mutation frequency group, including most of the microsatellitestable cancers (copy numberYlow group); and (4) the group consisting primarily of serous-like cancers with extensive copy number alterations and low mutation frequencies (copy numberYhigh group).
The ultramutated group (7% of tumors) was characterized by an increased somatic transversion frequency, with all the tumors having mutations in the exonuclease domain of the POLE gene (involved in nuclear DNA replication and repair). Surprisingly, this group was associated with favorable PFS, as the tumor cells possibly continued to accumulate unrepaired somatic mutations. The endometrioid tumors with microsatellite instability had a mutation frequency approximately 10-fold greater than microsatellite-stable endometrioid tumors with few copy number alterations. The microsatellitestable, copy numberYlow group had a high frequency of CTNNB1 mutations (52%), with this gene being the only one with a higher mutation frequency than in the microsatelliteunstable cases. The copy numberYhigh group contained most of the serous cases and approximately 25% of the grade 3 endometrioid cases. In addition to increased somatic copy number alterations, frequent TP53 mutations, and infrequent PTEN mutations, this group was characterized by few DNA methylation changes and low estrogen/progesterone receptor levels. In addition to the high frequency of TP53 mutations, these tumors also had a high frequency of FBXW7 and PPP2R1A mutations, a profile previously reported as common in uterine serous but not endometrioid cancers.
Additional analyses showed similar molecular features among USCs, high-grade serous ovarian carcinomas, and basallike breast carcinomas, including similar focal somatic copy number alteration and gene-expression patterns. These 3 subtypes share a high frequency of TP53 mutations (84%Y91%) and low frequency of PTEN mutations (1%Y2%), although the uterine serous cancers were found to have higher frequencies of FBXW7, PPP2R1A, PIK3CA, and ARID1A mutations than the high-grade serous ovarian carcinomas or basal-like breast tumors.
Atypical endometrial hyperplasia is frequently the precursor lesion in EEC, which is generally hormonally induced. In contrast, USC commonly arises in a background of endometrial atrophy. 9 Endometrial intraepithelial carcinoma may be the precursor lesion in USC, marked by cytologically malignantYappearing cells on the endometrial surface, which morphologically look like the cells of invasive serous carcinoma. This association has been further validated; Ambros et al 9 reported endometrial intraepithelial carcinoma in 98% of USC lesions, in contrast to only 6% of EEC tumors. Recently, endometrial glandular dysplasia has been proposed that it is the precursor lesion of UPSC. 10 Consensus opinion on clinical management of this new entity has not been well developed.
Diagnosis
Postmenopausal uterine bleeding is the most common symptom in women with USC. Endometrial sampling, including Pipelle biopsy carried out in the office setting, has been associated with a 99% sensitivity for detection of USC. 11 The diagnosis of USC is less specific when compared with other high-grade endometrial cancer histologic subtypes. This finding may be due in part to the fact that USC is often admixed with other high-grade endometrial-cancer histologies, including clear cell and EEC. 11 Positron emission tomography/computed tomography may be of value in the presurgical evaluation of patients with USC, in the assessment of extrauterine disease, and in operative planning. Although there is no known survival benefit, comprehensive surgical staging, inclusive of pelvic and para-aortic lymphadenectomy, is still recommended for all patients who are appropriate surgical candidates in order to identify those who have stage IIIc disease. ACRIN 6671/GOG 233 is an ongoing phase 2 study evaluating the role of positron emission tomography/ computed tomography imaging in the preoperative evaluation of patients with high-grade endometrial cancer.
Initial Treatment
As USC is relatively rare, USC has been included in prospective trials of endometrial cancer, although no randomized trials limited to only USC have been performed. Most of the available data are in the form of small, retrospective single-and multi-institutional studies. In some large randomized studies, this histologic subtype is grouped with other subtypes of endometrial cancer. The percentage of patients with USC accrued to these trials is only about 10% to 20%, making it difficult to have sufficient power to analyze this subgroup separately and be able to draw specific conclusions regarding therapy and outcome. 6 However, because of its aggressive behavior and pattern of recurrence, multimodality treatment, including surgery, chemotherapy, and radiotherapy, has been used in the management of USC.
Surgery
The initial management for the majority of women with USC is surgical exploration and comprehensive staging for early-stage disease or debulking for advanced cases (including omentectomy). A small number of reports describe neoadjuvant chemotherapy for patients who were supposed to be poor surgical candidates for upfront debulking. Although treatment of lymph nodes in the pelvis does not confer a survival benefit, diagnosis of positive nodes changes management and is therefore advised for high-risk patients. In a prospective randomized controlled trial (ASTEC study), pelvic lymphadenectomy in women with endometrial cancer was not associated with improved survival; however, in that study, only 4% of cases had USC, and subset analysis was not performed. 12 Similarly, in another randomized trial of endometrial endometrioid cancer patients, no survival benefit to lymphadenectomy was shown, although the question of a benefit for USC patients remains unanswered with a definitive prospective randomized trial. 13 FIGO staging for endometrial carcinoma mandates removal of the uterus, fallopian tubes, and ovaries, and pelvic and para-aortic lymphadenectomy. Abdominopelvic washings are collected but no longer impact staging. In USC cases, prognostic factors such as myometrial invasion or lymphovascular space invasion are important determinants of the risk of nodal disease. However, distant metastatic disease may be encountered even in the absence of these risk factors. In a series of 52 surgically staged women with USC, similar rates of lymph node and intraperitoneal metastases were reported in cases with either no myometrial invasion or deep invasion (36 vs 40% and 43 vs 35%, respectively).
14 A study of 84 patients with clinical stage I USC reported an OS advantage benefiting women undergoing comprehensive surgical staging compared with those treated only with hysterectomy and bilateral salpingo-oophorectomy (16.4 vs 2.76 years). 15 Stage migration and selection factors may have contributed to this difference. Another study of 206 women with surgically staged stage I-II USC demonstrated that recurrence and PFS were not associated with an increasing percentage of USC in the histologic specimen, lymphovascular space invasion, or tumor size. 16 Similar to epithelial ovarian cancer, USC often shows metastatic disease outside the pelvis. In one of the largest series of patients with advanced-stage USC, optimal cytoreduction was associated with a median survival of 39 months compared with 12 months in patients who underwent suboptimal surgery (P = 0.0001). 17 Maximal cytoreduction efforts should be made at the time of primary surgery for advanced-stage disease.
Adjuvant Therapy
Uterine serous carcinomas present a high risk of recurrence outside the pelvis, often in multiple sites, whereas recurrence in most women with early-stage EEC is in the vagina or pelvis. In this view, adjuvant therapy for USC with chemotherapy and/or radiation therapy is often used.
Chemotherapy

Early-Stage Disease
In the largest retrospective series of USC patients to date, significant survival benefits were reported with the use of chemotherapy and radiation. 18 A retrospective series with stage I USC only has reported improved relapse-free survival with platinum/taxane chemotherapy. 19 Among 142 women with surgical stage I USC, significantly improved rates of both recurrence and OS were associated with the addition of platinum/taxane chemotherapy with/without radiation. 19 Both PFS and cause-specific survival rates were better for women treated with chemotherapy. The impact chemotherapy had on recurrence rate, PFS, and cause-specific survival was most pronounced in patients with stages IB/IC USC. The role of adjuvant chemotherapy in the management of early-stage (I/II) USC lacks data from randomized studies, although in the randomized Nordic Society of Gynaecological Oncology (NSGO)/European Organisation for Research and Treatment of Cancer (EORTC) trial, which compared radiation alone with radiation and 4 cycles of adjuvant platinum-based chemotherapy, the 20% of patients (n = 74) with USC had no PFS or OS benefit from chemotherapy, in contrast to those with endometrioid cancers. 20 In a retrospective series of 74 patients, a recurrence rate of 43% was reported in patients with stage IA USC with residual cancer in the uterine specimen not offered adjuvant therapy. Using FIGO 1988 staging, the authors proposed that platinum-based chemotherapy and brachytherapy should be considered in all women with stage IA USC, except for those with no residual cancer in the uterus at time of hysterectomy. 21 It may be appropriate to offer women with stage IA USC platinum-taxaneYbased chemotherapy and radiation, with the possible exception of those USC with no residual disease in the uterine specimen. But it is still controversial. Several studies have reported high recurrence rates for patients with stages IB/IC USC, as staged according to the FIGO 1988 criteria. Reported 5-year survival rates for stages IA, IB, and IC are 81.5%, 58.6%, and 34.3%, respectively. The fact that 10% to 20% of women with stage I USC treated without systemic adjuvant therapy will have a recurrence suggests that USC may be offered platinum-based chemotherapy or brachytherapy. In an analysis of 103 women with surgically staged stage I USC all treated with vaginal brachytherapy and 35 also with chemotherapy, relapse rates were low, and chemotherapy did not affect recurrence or survival. 22 Retrospective studies show that women with stage IB USC could be treated with platinum-taxaneYbased systemic therapy with consideration of brachytherapy if patients have had a lymph node dissection. In the absence of nodal dissection, pelvic radiation is recommended in the United States (National Comprehensive Cancer Network Guidelines). Adjuvant chemotherapy and radiation are used in the management of stage II USC. In a retrospective study, with a median follow-up time of 33 months, 20 (36%) of 55 women with stage II USC had recurrent disease. 23 Most of the recurrences were detected within 2 years (85%) and were observed outside the pelvis (70%). In women treated with chemotherapy with or without radiation therapy, the reported recurrence rate was 11%, in contrast to 50% in those treated with radiation therapy only or observation (P = 0.013). None of the women treated with multimodality therapy experienced a recurrence.
Advanced-Stage and Recurrent Disease
The GOG has completed a series of phase 3 randomized prospective trials of chemotherapy for advanced-stage or recurrent endometrial carcinoma, of which 18% to 20% were USC.
24Y26 Studies of paclitaxel plus either carboplatin or cisplatin have shown response rates of 50% or higher, an improved PFS rate, and possibly prolonged survival compared with historical experience with other nonYpaclitaxel-containing regimens. Paclitaxel-based regimens may be more active in nonendometrioid adenocarcinoma histologies that tend to have a lower response to doxorubicin and/or cisplatin-based regimens. Paclitaxel-containing regimens have been reported to have response rates as high as 80% in recurrent or advanced USC. 26, 27 In a prospective phase 3 GOG study with 13% USC cases in each arm, the addition of paclitaxel to cisplatin and doxorubicin (TAP) following cytoreductive surgery and tumorvolumeYdirected radiation therapy was not associated with improvement in recurrence-free survival but resulted in greater toxicity as compared with carboplatin/paclitaxel (GOG184). Relative to grade 1 EEC, the rate of recurrence for USC was 4.43 times higher. 26 Subgroup analysis revealed that TAP was associated with a 50% reduction in the risk of recurrence or death among patients with gross residual disease. There was a trend toward improved outcomes in women with USC, although this did not reach statistical significance (hazard ratio, 0.73). Another phase 3 randomized trial (GOG 177) compared TAP to cisplatin and doxorubicin in women with advanced/metastatic or recurrent endometrial carcinoma. The 3-drug regimen was associated with an improved response rate (57% vs 34%), longer PFS (8.3 vs 5.3 months), and a slight improvement in survival (15.3 vs 12.3 months), but with significantly increased toxicity. 24 In the recent phase 3 trial, TAP was compared with carboplatin and paclitaxel (TC) in women with advanced-stage or recurrent endometrial cancer. A higher percentage of patients on TC were able to complete all 7 planned courses of treatment (69% vs 62% for TAP). The less toxic 2-drug (TC) regimen is not less effective and may offer greater clinical benefit in terms of adverse effects than the 3-drug (TAP) regimen. 27 However, each of the phase 3 GOG trials has included different histologies. Approximately 12% to 18% of the study populations in each of these trials were patients with USC. 26, 27 Although in 1 of these trials, recurrence-free survival varied with histology and grade, with USC having the poorest outcome, analysis of the combined data from 4 earlier GOG phase 3 trials failed to show an association between histology and response rate. 24, 26 These conflicting results and continued controversy as to the best management strategy in USC indicate the need for prospective trials inclusive only of this histology.
Radiation Therapy
Radiation therapy is commonly used as adjuvant treatment in the management of endometrial cancer. Retrospective series show a survival benefit to the combination of radiation with chemotherapy in USC. 18 Because of the tendency for USC to recur within the peritoneal cavity, historical studies of radiation therapy in the management of this disease have explored the role of whole-abdominal radiotherapy with a pelvic boost (whole abdominal and pelvic irradiation [WAPI] ). In the NSGO/EORTC study of early-stage, highrisk uterine cancer including 20% of patients with USC, the combination of radiation therapy and chemotherapy was superior to radiation therapy alone for endometrioid cancers, but this was not clear for USC. The hazard ratio for PFS was 0.64, favoring combination radiation and chemotherapy (P = 0.04). This translated to an estimated 7% absolute difference in 5-year PFS from 72% to 79%. For serous and clear cell cancers, PFS rates were 71% and 72% (P = 0.56). In the only prospective study of adjuvant radiation in women with earlystage USC, 21 patients were treated with WAPI. 28 Of 19 patients with evaluable disease, 9 died of recurrent USC, 5 of whom developed recurrent disease within the irradiated field. Ten patients remained disease-free. The role of brachytherapy in early (stage IAYIB) surgically staged USC has been investigated in a series of 103 patients and provided good local control. 22 Several studies have investigated the role of radiation therapy, ranging from tumor-directed radiation to WAPI, in the treatment of advanced-stage USC. The GOG conducted a randomized phase 3 trial (GOG 122) comparing WAPI to doxorubicin and cisplatin in women with stages III/IV endometrial cancer (residual disease G2 cm in greatest diameter) with 20% having USC. 25 Patients with USC did not seem to benefit from chemotherapy, in contrast to those with endometrioid histology. The currently accruing GOG 258 phase 3 study compares adjuvant chemotherapy plus radiation to chemotherapy alone. Both the appropriate timing of initiating chemotherapy and the most appropriate agents to use remain controversial. The potential benefit of multimodality treatment and the optimal sequence remain unclear. Further investigation via additional prospective trials is needed.
Management of Metastatic Disease
As noted earlier, USC often exhibits HER-2/neu overexpression. These findings have led some investigators to propose the use of the anti-HER2 monoclonal antibody, trastuzumab, in the management of USC. In the largest reported series of USC patients, HER-2/neu was overexpressed in 47% but rates of 26% to 62% positivity have been observed, depending on disease stage. 29 A clinical study failed to show single-agent activity of trastuzumab in patients with advancedstage or recurrent endometrial carcinoma whose tumors overexpressed HER2/neu. However, of all endometrial cancer subtypes, HER-2/neu appears to be most commonly expressed in USC. Therefore, there is a scientific rationale for studying platinum/taxane-based regimens with trastuzumab in this patient population. To date, trastuzumab therapy, either as monotherapy or in combination with chemotherapy, has not been well studied in USC. In a phase 2 trial of bevacizumab in recurrent or persistent endometrial cancer, 7 patients (13.5%) experienced clinical responses, which were seen across histologic type, although interestingly, 1 patient with a complete response and 3 of 6 patients with a partial response had serous histology, and the percentage of patients alive and progressionfree at 6 months was similar for serous and endometrioid histologies. 30 Patient numbers were too small to formally evaluate the role of histologic subtype and response to bevacizumab in that trial, but it is worthy of further study. Despite the limitations in sample size and exploratory nature of the studies, angiogenic markers in tumor and serum may prove to be of prognostic value in recurrent/persistent endometrial cancer.
Perspectives and Future Directions
As described earlier, the marked molecular differences between endometrioid and serous-like tumors suggest that they warrant separate clinical trials to develop the personalized treatment paradigms that have improved outcomes in other tumor types, such as breast cancer. One reasonable approach to the treatment of USC may lie in combination treatment with chemotherapy and targeted therapy. There is a scientific rationale for studying platinum/taxane-based regimens with trastuzumab. The discovery of genetic alterations of several intracellular pathways in USC offers the opportunity of adding targeted therapies to the treatment armamentarium in this disease. The optimal choice of an agent, used alone or in combination therapy, awaits the results of largerscale clinical trials to verify these agents' efficacy and safety. New genetic profiling analysis may allow more definitive diagnosis, and future studies should more accurately classify patients and uncover what therapeutic benefit a given treatment may provide.
CONCLUSIONS
Uterine serous carcinoma represents a rare and aggressive histologic subtype of endometrial cancer, associated with a poor prognosis. Both USC and approximately 25% of high-grade endometrioid tumors represent extensive copy number alterations, few DNA methylation changes, low estrogen and progesterone levels, and frequent P53mutations. Uterine serous carcinoma shares molecular characteristics with ovarian serous and basal-like breast carcinomas. In addition to optimal surgery, platinum-and taxane-based chemotherapy should be considered in the treatment of both early-and advanced-stage disease. The combination of radiation and chemotherapy appears to be associated with the highest survival rates. The role of radiation therapy in the management of this disease, with a high propensity for distant failures, remains elusive. Futures studies should identify the optimized chemotherapy and radiation regimens, sequence of therapy and schedule, and the role of targeted biologic therapy.
